TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01409031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Sildenafil
Description: 0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
Study: NCT04138056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix-ex-US
Description: One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Boostrix-ex-US
Description: One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix-US
Description: One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix-US
Description: One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Boostrix-US
Description: One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.
Study: NCT01772940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nevirapine
Description: Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nevirapine
Description: Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir-boosted Lopinavir
Description: ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir-boosted Lopinavir
Description: ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine
Description: tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/emtricitabine
Description: tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine/lamivudine
Description: zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine/lamivudine
Description: zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks
Study: NCT03281213

Intervention type: OTHER
Intervention: Thoracotomy

Intervention type: OTHER
Intervention: Thoracotomy
Study: NCT03849261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D635
Description: Reference drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D635
Description: Reference drug
Study: NCT01416350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin - 250 mg
Description: Part A - A single azithromycin dose of 250 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin - 1000 mg
Description: Part A - A single azithromycin dose of 1000 mg.
Study: NCT00554320

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: During each session, the anode electrode will be placed on the motor cortex (contralateral to the most \[or predominant\] painful side \[or the side where the symptoms begin or the left as a default\]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
Study: NCT01409031

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An equivalent volume of placebo (D5W)infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
Study: NCT03029416

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Stereotactic Body Radiation Therapy using different fractionation schedules

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Stereotactic Body Radiation Therapy using different fractionation schedules
Study: NCT00313599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT02391090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hypoxia in hypoxic chamber
Description: Intervention lasts 4 hours per day for 6 days in a row.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham hypoxia in hypoxic chamber
Description: Intervention lasts 4 hours per day for 6 days in a row.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Description: Pulse oximetry will be performed hourly during sessions in the hypoxic chamber for safety reasons.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pulse oximetry
Description: Pulse oximetry will be performed hourly during sessions in the hypoxic chamber for safety reasons.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma and Quality of Life Questionnaires
Description: Before every session in the hypoxic chamber as well as on the day after the last session will be completed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Asthma and Quality of Life Questionnaires
Description: Before every session in the hypoxic chamber as well as on the day after the last session will be completed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung function testing
Description: On the day of the first session in the hypoxic chamber as well as on the day after the last session lung function testing will be performed.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Lung function testing
Description: On the day of the first session in the hypoxic chamber as well as on the day after the last session lung function testing will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood taking
Description: On the day of the first session in the hypoxic chamber as well as on the day after the last session blood samples will be taken.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Blood taking
Description: On the day of the first session in the hypoxic chamber as well as on the day after the last session blood samples will be taken.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FeNO measurement
Description: Before every session in the hypoxic chamber as well as on the day after the last session FeNO (forced exhaled nitric oxide) measurement will be performed.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: FeNO measurement
Description: Before every session in the hypoxic chamber as well as on the day after the last session FeNO (forced exhaled nitric oxide) measurement will be performed.
Study: NCT00415389

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interactive educational program
Description: 2-session interactive stroke educational program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual medical care
Description: standard educational materials and usual care
Study: NCT02050724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radioactive labelling of pulmonary nodules
Description: Application directly into a pulmonary nodule
Study: NCT03664193

Intervention type: RADIATION
Group type: OTHER
Intervention: SIBRT
Description: Patients will receive 35 Gy in 5 fractions. Also, patients will receive 0.5-2 Gy per fx for a total dose of 37.5, 40, 42.5, or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy.
Study: NCT01613014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-436
Description: Target dose - 400mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo - Sugar Pill
Description: Target Dose - 2 pills BID
Study: NCT03577912

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block administered by Surgery
Description: TAP block administered by Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block administered by Anesthesia
Description: TAP block administered by Anesthesia
Study: NCT04302103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 160mg
Description: subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 240 mg
Description: subcutaneous injection
Study: NCT00896987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine (Lamictal)
Description: lamotrigine: titration for 8 weeks (25 mg\~200 mg per 2 weeks) and maintenance for 40 weeks (200 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine (Tegretol)
Description: Carbamazepine: titration for 8 weeks (100 mg\~600 mg) and maintenance for 40 weeks (600 mg)
Study: NCT02576964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Participants will receive SC peginterferon alfa-2a, 180 mcg every week during each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
Study: NCT01914887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose tissue-derived mesenchymal stem cells
Description: The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
Study: NCT02826733

Intervention type: DEVICE
Intervention: Electroencephalogram (EEG)
Study: NCT02050724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radioactive labelling of pulmonary nodules
Description: Application directly into a pulmonary nodule

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT guided radioactive labelling
Description: CT guided puncture is a standard procedure in radiology. In this study it is used to mark pulmonary nodules for the following thoracoscopic surgery, done with a handheld-SPECT device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic guided bronchoscopic radioactive labelling
Description: Electromagnetic guided bronchoscopy is a standard procedure. In this study it is used to mark pulmonary nodules.
Study: NCT00762619

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush twice daily
Study: NCT00554320

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
Study: NCT02826733

Intervention type: DEVICE
Intervention: Electroencephalogram (EEG)

Intervention type: DEVICE
Intervention: Near Infra Red Spectroscopy (NIRS)

Intervention type: DEVICE
Intervention: Near Infra Red Spectroscopy (NIRS)

Intervention type: DEVICE
Intervention: magnetic resonance imaging (MRI)

Intervention type: DEVICE
Intervention: magnetic resonance imaging (MRI)
Study: NCT01685359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Intravenous administration for 4 weeks, three times a week (monday, wednesday, friday)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Intravenous administration for 4 weeks, three times a week (monday, wednesday, friday)
Study: NCT01157416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine
Description: D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill by mouth prior to sessions 5-12 of the 12-session CBT protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: 12-session CBT protocol, called Youth PTSD Treatment.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT
Description: 12-session CBT protocol, called Youth PTSD Treatment.
Study: NCT02577250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
Study: NCT03241472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: oral tablets 5 mg
Study: NCT04610060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power walking
Description: Exercise in the form of Power walking at hospital for 10-20 minutes on treadmill with various exercise intensities. Weekly Steps at home 30 minutes walking with target to reach 1000 steps daily.~It is a form of exercise where active upper body movement is performed along with usual walking. It is a fast walking exercise done at a speed of 6 to 8 km/h. During power walking the back is kept straight with the centre of gravity moving from heal, sole, and to hallux. There is active swing back and forth movement of elbow joint with 90 degrees of flexion while walking.~Weekly protocol for power walking~* Week 1 60-65 % of the target heart rate (THR) 5,000 to 7,499 steps/day~* Week 2 65-70 % of the target heart rate (THR) 7,500 to 9,999 steps/day~* Week 3 70-75 % of the target heart rate (THR) \>=10,000 steps/day~* Week 4 75-80 % of the target heart rate (THR) \>12,500 steps per day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardised outpatient cardiac rehabilitation
Description: Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines the intervention group received the following four weeks of intense training program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardised outpatient cardiac rehabilitation
Description: Standardised Outpatient Cardiac Rehabilitation based on ACSM Guidelines the intervention group received the following four weeks of intense training program
Study: NCT02854696

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet graft
Description: Patients will be transplanted with pancreatic islet cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: best medical care
Description: Patients will continue their insulin treatment
Study: NCT03241472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate plus N acetyl cystine
Description: Clomiphene Citrate 100 mg oral tablets+ N acetyl cystiene 600 mg
Study: NCT03533725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding counseling and education services
Description: Breastfeeding counseling and education by educated and trained peer counselors using mHealth tools
Study: NCT03730883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central line removal at 100ml/kg/day.
Description: In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake if well tolerated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central line removal at 140ml/kg/day.
Description: In this group central line will be removed at the time the infant reaches 140 ml/kg/day of enteral intake if well tolerated.
Study: NCT01123122

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strict glucose control
Description: Blood glucose level to be maintained at 4-6 mmol/L at the time of islet transplantation until two weeks post-transplantation.
Study: NCT00932152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant (Faslodex)
Description: Fulvestrant (Faslodex) IM 250 mg monthly after a loading dose of 500 mg on day 1 and 250 mg on day 15 of cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant (Faslodex)
Description: Fulvestrant (Faslodex) IM 250 mg monthly after a loading dose of 500 mg on day 1 and 250 mg on day 15 of cycle 1.
Study: NCT03244475

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TES
Description: The EEG interface device is the J\&J Engineering I-330 C2. IASIS is delivered via the 4 EEG leads with respect to the Common Neck Reference. During each session, 2 electrodes are attached to the participant's left and right mastoids, while the remaining 2 electrodes are moved to various locations on the scalp to record EEG signals. All 4 electrodes are involved in applying weak electric current pulses back to the brain. The feedback signal consists 2 types of narrow pulse trains, both with 150mV in amplitude.~The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a waveform that provides tES to the brain delivered at a frequency of 4Hz, 40Hz, and 77.5Hz at 0 to 15mA peak current. Evidence shows this waveform, at these frequencies, results in improved clinical outcomes for anxiety and pain. We hypothesize that repeated TES treatments serve to stimulate long-term neurochemical changes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TES
Description: The EEG interface device is the J\&J Engineering I-330 C2. IASIS is delivered via the 4 EEG leads with respect to the Common Neck Reference. During each session, 2 electrodes are attached to the participant's left and right mastoids, while the remaining 2 electrodes are moved to various locations on the scalp to record EEG signals. All 4 electrodes are involved in applying weak electric current pulses back to the brain. The feedback signal consists 2 types of narrow pulse trains, both with 150mV in amplitude.~The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a waveform that provides tES to the brain delivered at a frequency of 4Hz, 40Hz, and 77.5Hz at 0 to 15mA peak current. Evidence shows this waveform, at these frequencies, results in improved clinical outcomes for anxiety and pain. We hypothesize that repeated TES treatments serve to stimulate long-term neurochemical changes.
Study: NCT02746627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect
Description: Positive psychology intervention to improve motivation for diabetes management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect
Description: Positive psychology intervention to improve motivation for diabetes management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Educational materials on diabetes management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Educational materials on diabetes management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Educational materials on diabetes management
Study: NCT00932152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole (Arimidex)
Description: Anastrozole (Arimidex) 1 mg orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole (Arimidex)
Description: Anastrozole (Arimidex) 1 mg orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Description: Bevacizumab (Avastin) 15 mg/kg IV, every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab (Avastin)
Description: Bevacizumab (Avastin) 15 mg/kg IV, every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care
Description: Subjects will not receive any chemotherapy for NSCLC nor will they received anti-cancer surgery, immunotherapy, radiotherapy or hormonal therapy. Among the therapies they may take are therapies considered acceptable include, but are not limited to, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care
Description: Subjects will not receive any chemotherapy for NSCLC nor will they received anti-cancer surgery, immunotherapy, radiotherapy or hormonal therapy. Among the therapies they may take are therapies considered acceptable include, but are not limited to, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral
Study: NCT01438749

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: Single doses (3 dose levels)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diazepam
Description: Single dose
Study: NCT02173496

Intervention type: OTHER
Intervention: Colour Contrast Sensitivity
Description: Reading of numbers or letters from a monitor
Study: NCT02710266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative Gabexate Mesilate group
Description: Gabexate Mesilate is administered from the preoperative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraoperative Gabexate Mesilate group
Description: Gabexate Mesilate is administered from the operative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hepatectomy with dextrose water
Description: Gabexate Mesilate is not administered. As placebo, 500cc of 5% dextrose water is administered at 40cc/hr for 12 hours
Study: NCT02493816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gene-modified autologous fibroblasts
Description: 3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.